# Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

> **NCT04474197** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 44 (actual)

## Conditions studied

- Alpha1-Antitrypsin Deficiency

## Interventions

- **DRUG:** VX-864
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04474197
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-24
- **Primary completion:** 2021-05-04
- **Final completion:** 2021-05-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04474197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04474197, "Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04474197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*